Please ensure Javascript is enabled for purposes of website accessibility
Value Investor
Wealth Building Opportunites for the Active Value Investor

Cabot Undervalued Stocks Advisor 621

Thank you for subscribing to the Cabot Undervalued Stocks Advisor. We hope you enjoy reading the June 2021 issue.

Many of our recommended names are at or approaching our price targets. The decision to keep or sell isn’t easy in a strong market. Our patience is being tested (in a good way).

Few people would attend the Indy 500 and think about investment horizons. But, such is the world that your chief analyst inhabits. The race itself was a thrill, as always. It was also a showcase of different investment horizons, featuring that of new track owner Roger Penske.

Earning season has concluded, so it has been a slow period for company-specific news, although Tyson (TSN) announced the surprise departure of its new CEO. Some companies, including Bristol-Myers (BMY), Cisco (CSCO) and Dow (DOW) are presenting at various investor conferences. These can be worthwhile to watch and are free to the public, with replays available in addition to the live presentations.

Please feel free to send me your questions and comments. This newsletter is written for you and the best way to get more out of the letter is to let me know what you are looking for.

I’m best reachable at Bruce@CabotWealth.com. I’ll do my best to respond as quickly as possible.

Thanks!

Cabot Undervalued Stocks Advisor 621

[premium_html_toc post_id="231541"]

The Indy 500 and Patience
Thank you for your patience with our one-day delay for this week’s Cabot Undervalued Stocks Advisor. Your chief analyst was away for an extended weekend trip to see the Indy 500 race.

The race itself is billed as “The Greatest Spectacle in Racing.” With 33 cars capable of speeds north of 230+ mph, driven by the most skilled drivers and backed by top crews competing at the highest level, it never disappoints. Part of the spectacle, no doubt, is the mix of 135,000 fans. Even at only 45% of full capacity due to Covid restrictions, the race drew nearly the largest number of fans of any sporting event in the world.

It was good to get away from the day-to-day deluge of media/information flow. I’m a voracious reader of information on the markets, companies, economy, geopolitical events and other current events. (I have zero use, however, for social media, as this information is either totally irrelevant or has a half-life of less than a minute, which is the same as irrelevant for a long-term contrarian investor).

Perhaps not everyone would see the Indy 500 from an investor’s perspective. But there it was, a range of businesses from “soda/beer sales from a cooler” to the immensely successful Roger Penske empire which now includes the Indianapolis Motor Speedway (IMS). The investment horizon for the cooler-based operations was “this afternoon,” requiring little patience. The horizon for Penske’s IMS investment: likely decades, despite his age (84). While the price he paid for the IMS hasn’t been disclosed, some estimates suggest a price of around $300 million. Penske’s patient approach, rather different from an asset-flipper approach, will help offset the awful timing of his purchase: January 2020, only months before the pandemic swept the world and nearly wiped out an entire year’s worth of revenue as fans were not allowed to attend live racing events. Despite the setback, Penske made further sizeable investments to upgrade the IMS track, evident as I walked around and chatted with a number of employees before the race.

Penske has been closely involved in racing and the on-road transportation industry for over half a century – first as a highly recognized driver (although he never drove in an Indy 500 race) and later as a team owner and business owner. Team Penske has won 18 Indy 500 races and has over 580 major race wins across open-wheel, stock car and sports car racing competition. One of his companies, Penske Automotive Group (PAG) is publicly traded. Its global operations produce $25 billion in revenues from its 323 car retailers, 29 commercial truck dealerships and the 28.9% stake in Penske Transportation Solutions. PAG shares have jumped 40% this year as the company is benefiting from the economy-wide reopening and from surging vehicle sales. Outside of the Penske Automotive Group is the Penske Corporation, which owns a range of related operations, Team Penske racing and the IMS. After building over a lifetime, starting with a $75,000 loan from his father in 1965 to purchase his first auto dealership, Roger Penske has earned his estimated $2.4 billion net worth.

Even the winner of this year’s Indy 500, 46-year-old Helio Castroneves, exhibited immense patience during the 2-hour, 40-minute race. He led for 20 laps but had to work his way through a crowded track, taking the final lead on lap 199 of the 200 lap race to win by less than half a second. Castroneves’ patience (and persistence) helped him win a record-tying fourth Indy 500.

Other comments
Several companies are presenting at investor conferences in coming weeks, including Bristol-Myers, Cisco, and Dow. The annual Bernstein Strategic Decisions Conference is notable, as it provides a high-level discussion of each company’s strategy. The conference is being held this week. Cisco is presenting on June 9th at Cowen’s Technology, Media and Telecom conference. Investors can access replays at each company’s (not the brokerage firm’s) investor relations website.

Share prices in the table reflect Tuesday (June 3) closing prices. Please note that prices in the discussion below are based on mid-day June 3 prices.

Note to new subscribers: You can find additional color on recent earnings and other news on recommended companies in prior editions and weekly updates of the Cabot Undervalued Stocks Advisor on the Cabot website.

Send questions and comments to Bruce@CabotWealth.com.

Upcoming Earnings Releases
None

Today’s Portfolio Changes
None

Portfolio changes during the past month
New Buy: Otter Tail Corporation (OTTR)

Growth & Income Portfolio

Growth & Income Portfolio stocks are generally higher-quality, larger-cap companies that have fallen out of favor. They usually have some combination of attractive earnings growth and an above-average dividend yield. Risk levels tend to be relatively moderate, with reasonable debt levels and modest share valuations.

Stock (Symbol)Date AddedPrice Added6/2/21Capital Gain/LossCurrent Dividend YieldPrice TargetRating
Bristol-Myers Squibb (BMY)04-01-2054.8264.6918.0%3.0%78.00Strong Buy
Cisco Systems (CSCO)11-18-2041.3252.9628.2%2.7%55.00Buy
Coca-Cola (KO)11-11-2053.5855.503.6%3.0%64.00Buy
Dow Inc (DOW) *04-01-1953.5068.9528.9%4.1%70.00Hold
Merck (MRK)12-9-2083.4775.87-9.1%3.4%105.00Buy
Otter Tail Corporaton (OTTR)5-25-2147.1048.302.5%3.2%57.00Buy
Tyson Foods (TSN)12-10-1988.6180.27-9.4%2.2%82.00Hold

Note: DOW price is based on April 1, 2019 closing price following spin-off from DWDP.

Bristol Myers Squibb Company (BMY) is a New York-based global biopharmaceutical company with over $45 billion in revenues. In recent years it has divested several major businesses to focus on high-value pharmaceuticals. BMY shares sell at a low absolute valuation and a sharp discount relative to peers due to worries over upcoming patent expirations for Revlimid (starting in 2022) and Opdivo and Eliquis (starting in 2026).

The shares are attractive for two reasons. First, low expectations (low valuation) minimize the downside risk should the anticipated weak fundamentals actually arrive, yet if the fundamental reality is stronger than feared the shares offer considerable upside potential.

Second, Bristol is reducing its fundamental risk through a multi-pronged revenue-and-profit-replacement strategy. Bristol has a robust pipeline of internally-developed treatments that offer potentially sizeable new revenues. Additionally, its acquisitions of Celgene and MyoKardia, and potentially future acquisitions, provide new growth potential that complements Bristol’s research expertise. And, Bristol has signed agreements with several generics competitors, reflecting the strong underlying demand for its “key three” products, such that the primary issue is pricing, not volumes.The shares are attractive for two reasons. First, low expectations (low valuation) minimize the downside risk should the anticipated weak fundamentals actually arrive, yet if the fundamental reality is stronger than feared the shares offer considerable upside potential.Bristol Myers Squibb Company (BMY) is a New York-based global biopharmaceutical company with over $45 billion in revenues. In recent years it has divested several major businesses to focus on high-value pharmaceuticals. BMY shares sell at a low absolute valuation and a sharp discount relative to peers due to worries over upcoming patent expirations for Revlimid (starting in 2022) and Opdivo and Eliquis (starting in 2026).

All-in, it is likely that the worst-case scenario is for flat revenues over the next 3-5 years. Any indication that revenues could sustainably grow should boost BMY’s share price considerably. Helping mitigating the risk, the company is aggressively cutting its costs, including a $2.5 billion efficiency program.

Earnings for 2021 are estimated to increase 16%, although tapering to 6-8% in future years. The company is positioned, backed by management guidance, to generate between $45 billion and $50 billion in cash flow over the three years of 2021-2023. This sum is equal to 35% of the company’s $144 billion market value. The balance sheet carries $13 billion in cash and its debt is only 2x EBITDA.

The first quarter 2021 earnings report delivered mixed news, so investors will need to remain patient. Revenue growth was a positive 3%, and earnings rose 1% but fell 4% below the consensus. Management reaffirmed their full year guidance for high single-digit (maybe 7-8%) revenue growth and for earnings between $7.35/share and $7.55/share, although the $7.45 midpoint was below the $7.48 consensus estimate.

There was no significant company-specific news in the past week.

BMY shares slipped 1% in the past week and have about 20% upside to our 78 price target. We remain patient with BMY shares.

The stock trades at a low 8.7x estimated 2021 earnings of $7.47 (unchanged from last week). On 2022 estimated earnings of $8.05 (unchanged), the shares trade at 8.1x. Either we are completely wrong about the company’s fundamental strength, or the market must eventually recognize Bristol’s earnings stability and power. We believe the earning power, low valuation and 3.0% dividend yield that is well-covered by enormous free cash flow make a compelling story. STRONG BUY.

BMY-060221

Cisco Systems (CSCO) produces technology equipment (72% of revenues) that connects and manages data and communications networks, and also sells application software, security software and related services. As customers gradually migrate to cloud computing, Cisco’s equipment, and thus its one-stop-shop capabilities, are slowly becoming less valuable, leading to stagnant revenue growth and weak stock performance. To help restore growth, Cisco is shifting toward a software and subscription model and ramping new products, helped by its strong reputation and its entrenched position within its customers’ infrastructure. Cisco’s prospects are starting to improve under CEO Chuck Robbins (since 2015). The company is highly profitable, generates vast cash flow (which it returns to shareholders through dividends and buybacks) and has a very strong balance sheet.

Cisco reported modestly encouraging fiscal third quarter results, with adjusted earnings per share of $0.83, up 5% from a year ago and a cent higher than the consensus estimate. Revenues rose 7% compared to a year ago (although much less when removing a 4% benefit for an extra week and for acquisitions) and were about 2% higher than consensus estimates. Fourth quarter guidance was good enough but was slightly shy of consensus estimates. The numbers are moving in the right direction, but need to show more improvement before the turnaround can be considered a success. More work is needed on profit margins, which continue to slip.

There was no significant company-specific news in the past week.

CSCO shares were flat in the past week and have about 4% upside to our 55 price target. While we generally would move the shares to a Hold, we believe Cisco’s earnings potential is higher than currently estimated, which leaves additional potential upside.

The shares trade at 16.4x estimated FY2021 earnings of $3.21 (unchanged in the past week). On FY2022 earnings (which ends in July 2022) of $3.41 (down a cent), the shares trade at 15.5x. On an EV/EBITDA basis on FY2021 estimates, the shares trade at a discounted 11.5x multiple. CSCO shares offer a 2.8% dividend yield. We continue to like Cisco. BUY.

CSCO-060221

Coca-Cola (KO) is best-known for its iconic soft drinks but nearly 40% of its revenues come from non-soda brands across the non-alcoholic spectrum, including PowerAde, Fuze Tea, Glaceau, Dasani, Minute Maid and Schweppes. Its vast global distribution system offers it the capability of reaching essentially every human on the planet.

Coca-Cola’s longer-term picture looks bright, despite the clouded near-term outlook due to the pandemic and the secular trend away from sugary sodas, its high exposure to foreign currencies and always-aggressive competition. Another overhang is the tax dispute that could cost as much as $12 billion – we don’t see an immediate resolution but consider $12 billion to be a worst-case scenario.

Relatively new CEO James Quincey (2017) is reinvigorating the company by narrowing its oversized brand portfolio, boosting its innovation and improving its efficiency. The company is also working to improve its image (and reality) of selling sugar-intensive beverages that are packaged in environmentally-insensitive plastic. Coca-Cola is supported by a sturdy balance sheet. Its growth investing, debt service and $0.42/share quarterly dividend are well-covered by free cash flow.

Coca-Cola’s first quarter results were encouraging, as the company’s revenues have nearly fully recovered from the pandemic. Still, investors will need to remain patient as on-premise sales remain subdued with consumers only slowly resuming their out-of-house activities. Adjusted earnings rose 8%. Free cash flow improved sharply to $1.4 billion, and the balance sheet remains strong. Coke reaffirmed its full-year guidance, which calls for 8-9% organic revenue growth and perhaps 8-12% comparable earnings per share growth.

There was no significant company-specific news in the past week.

KO shares rose 1% in the past week and have about 16% upside to our 64 price target. While the valuation is not statistically cheap, at 25.4x estimated 2021 earnings of $2.18 (unchanged in the past week) and 23.5x estimated 2022 earnings of $2.36 (unchanged), the shares remain undervalued given the company’s future earning power and valuable franchise. Also, the value of Coke’s partial ownership of a number of publicly traded companies (including Monster Beverage) is somewhat hidden on the balance sheet, yet is worth about $23 billion, or 9% of Coke’s market value. This $5/share value provides additional cushion supporting our 64 price target. KO shares offer an attractive 3.0% dividend yield. BUY.

KO-060221

Dow Inc. (DOW) merged with DuPont in 2017 to temporarily create DowDuPont, then split into three companies in 2019 based roughly along product lines. The new Dow is the world’s largest producer of ethylene/polyethylene, the most widely-used plastics. Dow is primarily a cash-flow story driven by three forces: 1) petrochemical prices, which are often correlated with oil prices and global growth, along with competitors’ production volumes; 2) volume sold, largely driven by global economic conditions; and 3) ongoing efficiency improvements (a never-ending quest of all commodity companies to maintain their margins).

Dow continues to participate in the economic recovery. For 2021, analysts estimate revenue growth to be 24%, aided by higher prices and volumes. The strong U.S. dollar may be a modest headwind as it makes revenues produced in other currencies less valuable. Generous free cash flow will partly be used to trim Dow’s debt.

First quarter results were strong, with adjusted earnings more than double the year-ago results and about 18% above the consensus of $1.15. Revenues rose 22% and were about 7% above consensus estimates. EBITDA rose 44%. Second quarter guidance was ahead of estimates and appears conservative. Dow’s balance sheet remains sturdy.

Two key questions for the Dow story: how much better can fundamentals get, and what will the company do with its vast free cash flow. Our view on the first is that conditions can get incrementally better over the next few quarters before capacity increases across the industry signal a cyclical peak. On the second, management’s cash flow priorities are to support the dividend, reduce its debt/pension liabilities, slowly ramp up capital spending, and repurchase shares. Current free cash flow readily supports all of these initiatives, so as long as the cycle remains robust investors can assume that debt paydown and share repurchases will continue. We are assuming no dividend increases, given the cyclicality of Dow’s business. We will continue our research into the company’s strategic use of its surplus cash.

There was no significant company-specific news in the past week.

Dow shares were flat this past week and are essentially at our 70 price target. For now, we suggest holding onto DOW shares, but we are reviewing the price target. The shares trade at 13.6x estimated 2022 earnings of $5.08 (up a cent this past week). The high 4.0% dividend yield adds to the shares’ appeal. HOLD.

DOW-060221

Merck (MRK) – Pharmaceutical maker Merck focuses on oncology, vaccines, antibiotics and animal health. The shares sell at a significant discount to its peers, as Keytruda, a blockbuster oncology treatment representing about 30% of total revenues, will face generic competition in late 2028. Also, hanging over the stock is possible generic competition for its Januvia diabetes treatment starting in 2022, and the possibility of government price controls.

Keytruda remains an impressive franchise that is growing at a 20+% annual rate. The company is becoming more aggressive about replacing the potentially lost revenues, even though it has nearly seven years to accomplish this. The new CEO, previously the CFO, will likely accelerate Merck’s acquisitive program, which adds both risk and return potential to the Merck story.

The company has spun off its Organon business as of June 2. Longer term, we see Merck spinning out or selling its animal health business. Merck has a solid balance sheet and is highly profitable. Longer term, the low valuation, strong balance sheet and sturdy cash flows provide real value. The 3.4% dividend yield pays investors to wait.

Merck’s first quarter earnings were lower than the market’s expectations, but our thesis remains unchanged. Sales of Keytruda (about a third of total sales) grew 19%, while Januvia (#2 product at about 10% of total sales) grew 1%. Gardasil fell 16%, attributed to changes in buying patterns in the U.S. and the timing of shipments to China. Sales for the Animal Health segment grew 17%. Merck’s earnings were weakened by the lower revenue and a modest narrowing of the gross margin. Net debt was essentially unchanged from year-end.

Merck’s spin-off of its women’s health, biosimilars and various legacy branded operations, named Organon (OGN), will begin regular trading on June 3. The new company will be included in the S&P 500 Index. When-issued trading began a few weeks ago and appear to be trading at around $35.50/share. We think the spin-off is a positive for Merck, as it trades away slow-growth operations for a $9 billion cash inflow. After the market’s close on June 2, MRK holders will receive one OGN share for every 10 MRK shares held.

Our initial view of Organon is that it has uninspiring but not dour prospects. The stock’s appeal would depend heavily on the price. In the mid-30s, we would begin to find it attractive.

Organon produces an array of established branded treatments (~68% of revenues), women’s health products (~23% of revenues) and biosimilars (a type of generic drug, at about ~9% of revenues). Revenues for 2021 should be about $6.6 billion. Revenue growth will be modest, at perhaps 3%, as the company’s products face patent-expiry erosion and generally are slow-growth. The marquee product is the Nexplanon contraceptive, which generates about 11% of sales – a valuable franchise but one that faces generic competition starting in 2028. Nearly 80% of Organon’s sales are produced outside of the U.S., offering some protection against faster patent-related erosion. A key component of its strategy is to accelerate its revenue growth. EBITDA profits will likely be about $2.3 billion (35% margin) this year.

The management seems capable but untested as leaders of a public company. Debt will be elevated at almost 4x EBITDA. Organon will produce good free cash flow which it will use to pay down the debt, fund a reasonable dividend (at 20% of FCF, its annual dividend would be perhaps $1.60/share) and fund acquisitions.

Merck shares slipped 2% this past week. The shares have about 39% upside to our 105 price target. Valuation is an attractive 11.7x this year’s estimated earnings of $6.47 (unchanged this past week). Merck produces generous free cash flow to fund its current dividend as well as likely future dividend increases, although its shift to a more acquisition-driven strategy will slow the pace of increases. BUY.

MRK-060221

Otter Tail Corporation (OTTR) – Based in northwest Minnesota, this $2 billion market cap company is a rare combination of an electric utility and a manufacturing business. Otter Tail’s power operations have a solid and high-quality franchise, with a balanced mix of generation, transmission and distribution assets that produce about 75% of the parent company’s earnings. An accommodative regulatory environment is allowing the utility to continue to add capacity, although its projected rate base growth is likely to be incrementally slower than in prior years.

The manufacturing side includes four well-managed specialized metals and plastics companies. Here, stronger end-market growth should more than offset rising input prices.

Otter Tail’s sturdy balance sheet is investment grade, earnings and cash flow are growing and the company prides itself on steady dividend growth. The unusual utility/manufacturing structure might make the company a target for activists, as the two parts may be worth more separately, perhaps in the hands of larger, specialized companies.

There was no significant company-specific news in the past week.

OTTR shares rose 2% in the past week and have about 17% upside to our 57 price target. The stock trades at about 18.6x estimated 2021 earnings of $2.61 (unchanged this past week) and offer an attractive 3.2% dividend yield. BUY.

OTTR-060221

Tyson Foods (TSN) is one of the world’s largest food companies, with nearly $43 billion in revenue. Beef products generate about 36% of total revenues, while chicken (31%), pork (10%), and prepared/other contribute the remaining revenues. It has the #1 domestic position in beef and chicken with roughly 21% market share in each. Its well-known brands include Tyson, Jimmy Dean, Hillshire Farms and Ball Park. Tyson’s long-term growth strategy is to participate in the growing global demand for protein. The company has more work to do to convince investors that its future is brighter, particularly as it is more of a commodity company (and hence has lower margins) compared to its food processor peers. Dean Banks, the new CEO, who previously was an Alphabet/Google executive, is starting to make necessary changes.

Tyson reported modestly discouraging fiscal second quarter results. Revenues were 4% above a year ago while adjusted earnings per share rose 68% from a year ago and was 16% higher than consensus estimates. However, the optically pleasing results were artificially boosted by hedging gains, leaving clean profits somewhat uninspiring. Pricing was strong across all segments. While the outlook for beef and pork is generally strong, the chicken segment is struggling with industry-wide and self-inflicted issues that the new chief operating officer is working to fix. Rising feedstock, labor and packaging costs are headwinds. The balance sheet has only incrementally improved since year-end.

The company’s new CEO, Dean Banks, is stepping down immediately (effective June 2) for personal reasons (these reasons were not specified) only eight months into the job. Current COO Donnie King will step up to the CEO seat. King is a long-time company veteran and seems fully capable of operating Tyson. CEO change-overs can be major events. In Tyson’s case, we don’t see much immediate impact. But, we have questions, starting with: why is CEO turnover so high (King is the fifth CEO in 5 years), why did Banks step down (truly personal, or are there company-related issues), will King embrace new technologies and strategies or just maintain the status-quo? Perhaps it was as simple as a Silicon Valley technology executive not being a good match for a Springdale, Arkansas chicken and beef company.

Competitor JBS (also the world’s largest meat producer, including majority-owned Pilgrim’s Pride), is re-starting its United States operations following a cyber-attack this past weekend. JBS shut down its entire domestic beef production. The impact on supplies appears minimal, given the quick recovery, but the disconcerting attacks in recent weeks, including the Colonial Pipeline, could have knock-on effects that aren’t yet foreseeable. We’d anticipate that these companies (probably all companies) will increase their tech spending in coming quarters to harden their systems against future attacks.

TSN shares rose 1% in the past week and continues to trade just below our recently raised 82 price target. As such, we are reviewing these Hold-rated shares.

While the near-term outlook is mixed, the new management is likely being conservative with its forward guidance. Valuation is reasonable at 13.5x estimated 2021 earnings of $5.95 (unchanged in the past week). Currently the stock offers a 2.2% dividend yield. HOLD.

TSN-060221

Buy Low Opportunities Portfolio

Buy Low Opportunities Portfolio stocks include a wide range of value opportunities, often with considerable upside. This group may include stocks across the quality and market cap spectrum, including those with relatively high levels of debt and a less-clear earnings outlook. The stocks may not pay a dividend. In all cases, the shares will trade at meaningful discounts to our estimate of fair value.

Stock (Symbol)Date AddedPrice Added6/2/21Capital Gain/LossCurrent Dividend YieldPrice TargetRating
Arcos Dorados (ARCO)04-28-215.416.7825.3%7.50Buy
Aviva (AVVIY)03-03-2110.7511.759.3%5.0%14.00Buy
Barrick Gold (GOLD)03-17-2121.1324.1714.4%1.5%27.00Buy
General Motors (GM)12-31-1936.6059.6563.0%62.00Hold
Molson Coors (TAP)08-05-2036.5360.1064.5%59.00Buy
Sensata Technologies (ST)02-17-2158.5760.102.6%75.00Buy

Arcos Dorados (ARCO) – Spanish for “golden arches,” Arcos Dorados is the world’s largest independent McDonald’s franchisee, operating over 2,200 restaurants and holding exclusive rights in 20 Latin American and Caribbean countries. Based in stable Uruguay and listed on the NYSE, the company produces about 72% of its revenues in Brazil, Mexico, Argentina and Chile. Arcos’ leadership looks highly capable, led by the founder/chairman who owns a 38% stake.

The pandemic has weighed on revenues, while the Venezuelan economic mess, political/social unrest, inflation and currency devaluations in other countries create profit headwinds and investor angst. The company is well-managed and positioned to benefit as local economies reopen. Debt is reasonable relative to post-recovery earnings, and the company is currently producing positive free cash flow, which buy it time until the recovery arrives.

Arcos reported a mixed quarter. Revenue fell 9% but rose 3.8% in constant currencies. The sharp depreciation of its local currencies, primarily the Brazilian real and Argentine peso, took 13 percentage points off of its US$-reported revenues compared to a year ago. EBITDA fell 18% in US$ but only 9.4% in constant currency after some reasonable adjustments. Local results showed improvement, which is part of our thesis on Arcos. Brazil struggled due to rising Covid-related restrictions but these are being lifted in early May. Net debt remained essentially unchanged from year-end.

There was no significant company-specific news in the past week. However, the pandemic appears to be weakening after ravaging Brazil this spring, helping boost ARCO shares. Also, a recent medical study, in which an entire Brazilian town of about 45,000 was nearly fully-vaccinated, concluded that the vaccine was instrumental in a near-erasure of Covid cases, providing more encouraging news.

ARCO shares rose 7% this past week to post-Covid highs and have about 13% upside to our 7.50 price target. The stock trades at 22.1x estimated 2022 earnings per share of $0.30 (unchanged from a week ago). BUY.

ARCO-060221

Aviva, plc (AVVIY) – Based in London, England, Aviva is a major European insurance company specializing in life insurance, savings and investment management products. Long a mediocre company, the frustrated board last July installed Amanda Blanc as the new CEO, with the task of fixing the business. She is aggressively re-focusing the company on its core geographic markets (UK, Ireland, Canada). The turnaround also includes improving Aviva’s product competitiveness, rebuilding its financial strength and trimming its bloated costs. The new leadership reduced the company’s recurring dividend, but to a more predictable and sustainable level, along with what is likely to be a modest but upward trajectory.

Aviva’s surplus cash flow, partly from divestitures, will be directed toward debt reduction and the recurring dividend. As it is over-capitalized, Aviva will pay out potentially sizeable special dividends to shareholders.

The company provided a first quarter trading update, which includes revenues and capital strength but not profits. Results were encouraging, yet more improvement is needed. Sales of its life insurance and annuity segment were flat, although much of this was due to lower annuities sales which appear to be caused by temporary delays, which are now reversing. Savings & Retirement sales increased 23%. General insurance premiums rose 4%, and the combined operating ratio was an encouraging 90.6%. The combined operating ratio is a measure of the claims and operating costs compared to sales, such that a 90.6% ratio means that profits were about 9.4% of sales, a good number. Aviva reiterated its full-year guidance for a ratio of below 95%, which is still healthy.

Capital strength continues to improve, even as the company set aside funds for dividends and repaid some of its debt.

The company said that the £7.5 billion in cash proceeds from the completion of its ambitious global divestiture program are now expected by year-end, sooner than previously anticipated. Aviva can now fully concentrate on improving the performance of its remaining core businesses.

Aviva’s shares will generally benefit as global interest rates start to tick up.

Aviva shares rose 3% this past week and have about 19% upside to our 14 price target. The stock trades at 7.7x estimated 2021 earnings per ADS of $1.53 (unchanged this past week) and at about 95% of tangible book value. AVVIY shares offer an attractive and likely solid and recurring 4.9% dividend yield. BUY.

AVVIY-060221

Barrick Gold (GOLD) – Toronto-based Barrick is one of the world’s largest and highest quality gold mining companies. About 50% of its production comes from North America, with 32% from Africa/Middle East and 18% from Latin America/Asia Pacific. Our thesis is based on two points. First, that Barrick will continue to improve its operating performance (led by its new and highly capable CEO), continue to generate strong free cash flow at current gold prices, and return much of that free cash flow to investors while making minor but sensible acquisitions. Second, Barrick shares offer optionality – if the enormous fiscal stimulus, rising taxes and heavy central bank bond-buying produces stagflation and low interest rates, then the price of gold will move upward and lift Barrick’s shares with it. Given their attractive valuation, the shares don’t need this second (optionality) point to work – it offers extra upside.

Major risks include the possibility of a decline in gold prices, production problems at its mines, a major acquisition and/or an expropriation of one or more of its mines.

Barrick reported encouraging first quarter results. Revenues rose 9% from a year ago, helped by higher gold prices and higher copper revenues, partly offset by a 10% decline in gold volumes. Adjusted EBITDA rose 23%, and overall free cash flow was strong, Barrick remains on-track to meet its full-year production guidance, and the balance sheet net cash position improved to $500 million. Barrick announced the first $0.14/share extra dividend, to be paid on June 15th, with two more later this year.

There was no significant company-specific news in the past week.

Barrick shares slipped 1% this past week and have about 11% upside to our 27 price target. The price target is based on 7.5x estimated 2021 EBITDA and a modest premium to its $25/share net asset value. Commodity gold ticked up to $1,909/ounce.

On its recurring $.09/quarter dividend, GOLD shares offer a reasonable 1.5% dividend yield. Barrick will pay an additional $0.42/share in special distributions this year, lifting the effective dividend yield to 3.2%. BUY.

GOLD-060221

General Motors (GM) – GM is making immense progress with its years-long turnaround from a poorly-managed post-bankruptcy car maker to a highly profitable gas and electric vehicle producer. We would say it is perhaps 85% of the way through its gas-powered vehicle turnaround, and is well-positioned but in the early stages of its EV development. GM Financial will likely continue to be a sizeable profit generator.

GM’s shares are at least partly trading on the prospects for President Biden’s $2 trillion infrastructure bill, which include as much as $100 billion in federal support for electric vehicles.

First quarter results were strong despite concerns over the semiconductor shortage. Automotive revenues were unchanged but higher vehicle prices drove adjusted net income to $2.25/share, sharply higher than the $0.62/share a year ago and the $1.05/share consensus estimate. GM Financial remains highly profitable. GM’s Automotive balance sheet remains sturdy, with cash of $19 billion fully offsetting automotive debt of $18 billion. We are wary of GM’s vast capital spending although we recognize the merits of high EV investments. The company reaffirmed its guidance for full-year EBIT of $10-11 billion. GM is fully-charged for both today’s environment and the EV world of the future, although much of its value is based on the unknown EV future.

Automobile chip maker Renesas said that it has returned to nearly-full production sooner than anticipated following a devastating March 19th fire. GM said it will re-start production at five assembly plants this week or next week as tight chip supplies appear to be easing. However, the global chip shortage will likely curtail car and truck industry production throughout the year.

GM shares rose 3% this past week and have 4% upside to our 62 price target. We remain on the border of selling this stock, given the risks, but for now are keeping the Hold rating. On any meaningful strength in the shares, we could move to a Sell.

On a P/E basis, the shares trade at 9.0x estimated calendar 2022 earnings of $6.63 (unchanged this past week). The P/E multiple is helpful, but not a precise measure of GM’s value, as it has numerous valuable assets that generate no earnings (like its Cruise unit, which is developing self-driving cars and produces a loss), its nascent battery operations, its Lyft stake and other businesses with a complex reporting structure, nor does it factor in GM’s high but unearning cash balance which offsets its interest-bearing debt. However, it is useful as a rule-of-thumb metric, and provides some indication of the direction of earnings estimates, and so we will continue its use here.

Our 62 price target is based on a more detailed analysis of GM’s various components and their underlying valuation. HOLD.

GM-060221

Molson Coors Beverage Company (TAP) – The thesis for this company is straight-forward – a reasonably stable company whose shares sell at an overly-discounted price. One of the world’s largest beverage companies, Molson Coors produces the highly recognized Coors, Molson, Miller and Blue Moon brands as well as numerous local, craft and specialty beers. About two-thirds of its $10 billion in net revenues are produced in the United States, where it holds a 24% share of the beer market.

Investors’ primary worry about Molson Coors is its lack of meaningful (or any) revenue growth as it produces relatively few of the fast-growing hard seltzers and other trendier beverages. Our view is that the company’s revenues are resilient, it produces generous cash flow and is reducing its debt – traits that are value-accretive and underpriced by the market. A new CEO is helping improve its operating efficiency and expand carefully into growthier products.

Molson is estimated to produce about 5% revenue growth and a 1% decline in per share earnings in 2021. Profit growth is projected to increase to a 5-9% rate in future years. Weakness this year is closely related to the sluggish reopening of the European economies, along with higher commodity and marketing costs. The company will likely reinstate its dividend later this year, which could provide a 2.4% yield.

Molson Coors’ first quarter results were encouraging, as revenues and profits showed respectable resilience and were better than consensus estimates despite headwinds from the pandemic, winter storms and a cyber-security problem. Revenues fell 10% while underlying EBITDA fell 21%. The company maintained its full year guidance,

There was no significant company-specific news in the past week.

TAP shares rose 1% in the past week and are at our 59 price target. The shares trade at 15.0x estimated 2021 earnings of $3.87 (unchanged this past week). Estimates for 2022 were unchanged at $4.20.

On an EV/EBITDA basis, or enterprise value/cash operating profits, the shares trade for about 9.7x current year estimates, still among the lowest valuations in the consumer staples group and below other brewing companies.

As the shares are at our price target and have largely fully recovered from the pandemic, we are evaluating the position. Molson Coors is a stable company trading at a low valuation with contrarian appeal. However, the upside from here is less clear but still may be plenty interesting. BUY.

TAP-060221

Sensata Technologies (ST) is a $3 billion (revenues) producer of an exceptionally broad range (47,000 unique products) of sensors used by automotive, industrial, heavy vehicle and aerospace customers. These products are typically critical components, yet since they represent a tiny percentage of the end-products’ total cost, they generally can yield high profit margins. Also, they tend to have relatively high switching costs – vehicle makers are reluctant to switch to another supplier that may have lower prices but lower or unproven quality. Sensata is showing healthy revenue growth, produces strong profits and free cash flow, has a reasonably sturdy balance sheet and a solid management team. The company was founded in 1916, owned by Texas Instruments for decades, and returned to public ownership in 2010.

Sensata’s growth prospects look appealing. The company is leveraged to the automobile cycle (about 60% of revenues), which provides cyclical growth, plus added growth as Sensata usually grows faster than the industry. It should benefit from overall economic growth as it serves trucking, construction, industrial and aerospace customers. As vehicles become more electrified, Sensata’s products will be used for more applications, further driving revenues. Recently, Sensata acquired Lithium Balance, which provides it with a valuable entre into the electric vehicle battery industry.

Risks include a possible automotive cycle slowdown, chip supply issues, geopolitical issues with China and difficulty integrating its acquisitions.

Revenues this year are projected to increase by about 24%, driven by a cyclical rebound, then taper to a 6% rate in future years. Profit growth of 54% in 2021, also boosted by the recovery, is estimated to taper to about 10-20% in future years.

Sensata reported strong first quarter results, with adjusted earnings about 62% above year-ago results and 18% above consensus estimates. Revenues were a record high, about 22% above year-ago revenues, and about 6% above consensus estimates. The company raised its full-year earnings guidance. Net debt was unchanged from the prior quarter as the company used surplus cash for acquisitions and capital spending.

There was no significant company-specific news in the past week. Generally, favorable news about the easing of the semiconductor shortage is favorable to Sensata.

ST shares rose 3% this past week and have about 25% upside to our 75 price target.

The stock trades at 14.7x estimated 2022 earnings of $4.06 (up 2 cents this past week). On an EV/EBITDA basis, ST trades at 12.8x estimated 2022 EBITDA. BUY.

ST-060221

Disclosure: The chief analyst of the Cabot Undervalued Stocks Advisor personally holds shares of every recommended security, except for “New Buy” recommendations. The chief analyst may purchase or sell recommended securities but not before the fourth day after any changes in recommendation ratings has been emailed to subscribers. “New Buy” recommendations will be purchased by the chief analyst as soon as practical following the fourth day after the newsletter issue has been emailed to subscribers.

Strong Buy – This stock offers an unusually favorable risk/reward trade-off, often one that has been rated as a Buy yet the market has sold aggressively for temporary reasons. We recommend adding to existing positions.
Buy – This stock is worth buying.
Hold – The shares are worth keeping but the risk/return trade-off is not favorable enough for more buying nor unfavorable enough to warrant selling.
Retired – This stock has been removed from the portfolio, primarily for being fully valued. We generally view the company as fundamentally solid with few problems. Investors may choose to hold these shares to minimize portfolio turnover, seek to capture continued upward share price momentum, or other reasons.
Sell – This stock is approaching or has reached our price target, its value has become permanently impaired or changes in its risk or other traits warrant a sale.


The next Cabot Undervalued Stocks Advisor issue will be published on July 7, 2021.

Cabot Wealth Network
Publishing independent investment advice since 1970.

President & CEO: Ed Coburn
Chief Investment Strategist: Timothy Lutts
Cabot Heritage Corporation, doing business as Cabot Wealth Network
176 North Street, PO Box 2049, Salem, MA 01970 USA
800-326-8826 | support@cabotwealth.com | CabotWealth.com

Copyright © 2021. All rights reserved. Copying or electronic transmission of this information without permission is a violation of copyright law. For the protection of our subscribers, copyright violations will result in immediate termination of all subscriptions without refund. Disclosures: Cabot Wealth Network exists to serve you, our readers. We derive 100% of our revenue, or close to it, from selling subscriptions to our publications. Neither Cabot Wealth Network nor our employees are compensated in any way by the companies whose stocks we recommend or providers of associated financial services. Employees of Cabot Wealth Network may own some of the stocks recommended by our advisory services. Disclaimer: Sources of information are believed to be reliable but they are not guaranteed to be complete or error-free. Recommendations, opinions or suggestions are given with the understanding that subscribers acting on information assume all risks involved. Buy/Sell Recommendations: are made in regular issues, updates, or alerts by email and on the private subscriber website.

Subscribers agree to adhere to all terms and conditions which can be found on CabotWealth.com and are subject to change. Violations will result in termination of all subscriptions without refund in addition to any civil and criminal penalties available under the law.